Teijin Pharma to Co-market New Anti-inflammatory Analgesic Patch Formulation

Tokyo, Japan, February 1, 2016 --- Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today that it launched LOQOA® Tape, a new transdermal anti-inflammatory analgesic patch formulation, on January 21, co-marketed with Taisho Toyama Pharmaceutical Co., Ltd. of the Taisho Pharmaceutical Group.

Outline of Approval
Generic Name
S-flurbiprofen and mentha oil
Indication and Usage
Treatment of pain and inflammation on osteoarthritis
Dosage and Administration
Apply to the lesion area once daily.
Do not apply more than two patches simultaneously
Price
45.90JPY(10cm×14cm per sheet)






By launching LOQOA® Tape, Teijin Group looks forward to improving the quality of life for osteoarthritis patients.

LOQOA® Tape was co-developed by Taisho Pharmaceutical Co., Ltd. and TOKUHON Corporation, a Taisho Pharmaceutical subsidiary, and received manufacturing and marketing approval in September 2015. It contains the active ingredients S-flurbiprofen, which is the active form of flurbiprofen, and mentha oil. The patch formulation is
designed to provide enhanced drug absorption to the inflamed area. In clinical trials, LOQOA® Tape was found to demonstrate a superior efficacy and a good safety profile in connection with osteoarthritis.

In Japan, an estimated 24 million people have knee osteoarthritis and 35 million people have lumbar spondylosis, approximately 30% of whom have pain symptoms. As this pain often reduces the patient's quality of life, there are high hopes for new patch formulations that could act as powerful anti-inflammatory analgesics.

Teijin Group is focusing on bone and joint diseases as one of the key therapeutic targets of its medical and pharmaceutical businesses. The company agreed with Taisho Pharmaceutical Co., Ltd. for the distribution rights in Japan to LOQOA® Tape in March 2015.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 150 companies and around 16,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY786.2 billion (USD 6.6 billion) and total assets of JPY 823.7 billion (USD 6.9 billion) in the fiscal year ending March 31, 2015. Please visit www.teijin.com.

Press Contact
Corporate Communications
Teijin Limited
+81 3 3506 4055
[email protected]

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.